- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00006168
Ursodiol-Methotrexate for Primary Biliary Cirrhosis
January 12, 2010 updated by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
The major thrust is to determine whether treatment of patients with Primary Biliary Cirrhosis (PBC) with Ursodiol (Ursodeoxycholic Acid-UDCA) plus methotrexate (MTX) is more effective than treatment with UDCA alone.
Study Overview
Detailed Description
PBC is a chronic cholestatic liver disease, predominantly of women, in which interlobular and septal bile ducts undergo inflammation and destruction.
Once initiated, the disease persists and progresses at varying rates.
Neither the initiating nor perpetuating mechanisms are well understood.
Current concepts of pathogenesis include (1) destruction of bile ducts is maintained and perhaps initiated by autoimmune mechanisms; (2) hydrophobic bile acids which accumulate in serum and liver cause functional and cytotoxic liver injury; (3) cytokines and lymphokines released at sites of inflammation may contribute to cell damage and fibrosis.
A considerable body of evidence indicates that UDCA when fed orally leads to improvement in liver tests, in pruritus and in liver histology.
There exist differences in opinion as to whether development of complications of liver disease, liver transplantation or transplant-free survival is affected.
UDCA, a relatively non-toxic bile acid, when administered orally, alters the composition of the bile acid pool in factor of its enrichment with UDCA and appears to protect against the cytotoxic effects of endogenous bile acids that accumulate as a result of bile acid destruction.
MTX is being shown to improve liver tests, symptoms and liver histology in a small number of precirrhotic patients with PBC.
The mechanism of action is unknown but felt to be related to anti-inflammatory immunosuppressive effects of MTX.
The current trial explores whether MTX improves the therapeutic effects of UDCA in PBC.
Patients with PBC whose serum bilirubin is less than 3 mg%, who have been on UDCA for at least 6 months, and who satisfy a series of inclusion and exclusion criteria are stratified into 2 groups on the basis of liver histologic stage (Ludwig classification), i.e., early (Stages I and II) versus late (Stages III or IV).
They are then randomized to receive either methotrexate or its placebo as a second drug while continuing to receive UDCA.
The relative value of the two treatment arms is assessed by comparing their effects on symptoms, results of laboratory tests, development of complications of liver disease, histologic changes in liver, liver transplantation, and on transplant-free survival.
The safety of each therapeutic regimen is also being determined.
Study Type
Interventional
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- Keck School of Medicine at U.S.C.
-
San Francisco, California, United States, 94143
- U California Medical Center
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520-8019
- Yale University School of Medicine
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University School of Medicine
-
-
Missouri
-
St. Louis, Missouri, United States, 63104
- Saint Louis University
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198-3285
- University of Nebraska Medical Center
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, United States, 97201
- Oregon Health Sciences University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19141
- Albert Einstein Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75235-9151
- UT Southwestern Medical Center at Dallas
-
-
Virginia
-
Richmond, Virginia, United States, 23298-0711
- Medical College of Virginia
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 69 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Chronic cholestatic liver disease of at least 6 months' duration.
- Serum alkaline phosphatase levels at least 1.5 times the upper limit of normal prior to treatment with UDCA.
- Serum bilirubin less than 3.0 mg% prior to treatment with UDCA.
- Serum albumin of 3.0 gram% or greater prior to treatment with UDCA.
- Positive antimitochondrial antibody test
- Liver biopsy within the previous 6 months after at least 6 months on UDCA (available for review, and at least 2 cm long if cirrhosis not detected) compatible with the diagnosis of PBC.
- Ultrasound, computed tomography (CT) or cholangiography of the biliary tree which excludes biliary obstruction.
Exclusion Criteria:
- Treatment with immunosuppressive agents including azathioprine, chlorambucil, colchicine, corticosteroids, or d-penicillamine in the preceding 3 months; or with cyclosporine, FK-506 or methotrexate in the preceding 6 months.
- Treatment with rifampin in the preceding 3 months.
- Serum bilirubin of 3.0 mg% or greater.
- Serum albumin less than 3.0 gm%.
- WBC 2,500 mm3; granulocytes 1,500 mm3; platelets 80,000mm3.
- Ascites, hepatic encephalopathy, variceal bleed.
- Findings by clinical, serologic and histologic evidence of liver disease of other etiology (such as chronic hepatitis B or C, autoimmune chronic active hepatitis, alcoholic liver disease, sclerosing cholangitis, drug-induced liver disease, symptomatic or obstructive gallstones).
- Pregnancy, or if not pregnant and in the reproductive period, unwillingness to utilize an adequate form of birth control.
- Age less than 20 or greater than 69 years.
- Epilepsy requiring use of dilantin.
- Malignant disease within the past 5 years (except skin cancer)
- Anti-HIV positive. Major illnesses that could limit life span.
- History of alcoholism during the previous 2 years.
- Creatinine clearance less than 60 ml per minute.
- Severe lung disease, defined as a diffusion capacity or vital capacity of less than 50 percent of predicted.
- Patients who are both asymptomatic and have Stage I histology on liver biopsy (Ludwig classification).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Masking: Double
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med. 1991 May 30;324(22):1548-54. doi: 10.1056/NEJM199105303242204.
- Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, Minuk GY, Pappas SC, Scully LJ, et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1994 May;19(5):1149-56.
- Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, Wiesner RH, Anderson ML, Lange SM, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994 May;106(5):1284-90. doi: 10.1016/0016-5085(94)90021-3.
- Combes B, Carithers RL Jr, Maddrey WC, Lin D, McDonald MF, Wheeler DE, Eigenbrodt EH, Munoz SJ, Rubin R, Garcia-Tsao G, et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1995 Sep;22(3):759-66.
- Kaplan MM, Knox TA, Arora SA. Primary biliary cirrhosis treated with low-dose oral pulse methotrexate. Ann Intern Med. 1988 Sep 1;109(5):429-31. doi: 10.7326/0003-4819-109-5-429. No abstract available.
- Kaplan MM. Methotrexate treatment of chronic cholestatic liver diseases: friend or foe? Q J Med. 1989 Aug;72(268):757-61. No abstract available.
- Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology. 1991 Nov;101(5):1332-8. doi: 10.1016/0016-5085(91)90085-y.
- Bergasa NV, Jones A, Kleiner DE, Rabin L, Park Y, Wells MC, Hoofnagle JH. Pilot study of low dose oral methotrexate treatment for primary biliary cirrhosis. Am J Gastroenterol. 1996 Feb;91(2):295-9.
- Buscher HP, Zietzschmann Y, Gerok W. Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone. J Hepatol. 1993 Apr;18(1):9-14. doi: 10.1016/s0168-8278(05)80004-2.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 1994
Study Completion
March 1, 2004
Study Registration Dates
First Submitted
August 8, 2000
First Submitted That Met QC Criteria
August 8, 2000
First Posted (Estimate)
August 9, 2000
Study Record Updates
Last Update Posted (Estimate)
January 13, 2010
Last Update Submitted That Met QC Criteria
January 12, 2010
Last Verified
January 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Liver Diseases
- Biliary Tract Diseases
- Bile Duct Diseases
- Cholestasis, Intrahepatic
- Cholestasis
- Fibrosis
- Liver Cirrhosis
- Liver Cirrhosis, Biliary
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Methotrexate
Other Study ID Numbers
- PUMPS (completed)
- 5R01DK046602 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cirrhosis, Biliary
-
University Health Network, TorontoUnknown
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingPrimary Biliary CirrhosisChina
-
CymaBay Therapeutics, Inc.TerminatedPrimary Biliary Cirrhosis (PBC)Germany, United States, Canada, United Kingdom, Poland
-
University Health Network, TorontoUnknownLiver Cirrhosis, Biliary | Biliary Cirrhosis, PrimaryCanada
-
Xijing Hospital of Digestive DiseasesUnknownPrimary Biliary CirrhosisChina
-
Xijing Hospital of Digestive DiseasesRecruitingPrimary Biliary CirrhosisChina
-
Intercept PharmaceuticalsCompletedLiver Cirrhosis, BiliaryUnited States, France, Germany, Spain, United Kingdom, Canada, Austria
-
Dr. Falk Pharma GmbHCompletedPrimary Biliary CirrhosisGermany
-
Instituto Nacional de Ciencias Medicas y Nutricion...UnknownPrimary Biliary CirrhosisMexico
-
University of FloridaShionogi Inc.; The PBCers OrganizationCompleted
Clinical Trials on Methotrexate
-
University Hospital, MontpellierPfizer; Hôpital CochinCompletedRheumatoid ArthritisFrance, Monaco
-
Nicolaus Copernicus UniversityCompleted
-
Amneal Pharmaceuticals, LLCAccutest Research Laboratories (I) Pvt. Ltd.Unknown
-
Hee Young JuNot yet recruitingLymphoblastic Leukemia in Children
-
PfizerCompletedRheumatoid ArthritisUnited States, Mexico, Argentina, Chile, Croatia, Czech Republic, Hungary, Poland, Puerto Rico
-
PfizerCompletedRhematoid ArthritisSpain, United Kingdom, United States, Korea, Republic of, Poland, Israel, Australia, Taiwan, Thailand, South Africa, Bulgaria, Estonia, Latvia, Philippines, Canada, Romania, Russian Federation, Turkey, Mexico, Bosnia and Herzegovina and more
-
Cairo UniversityCompleted
-
Chugai Pharma TaiwanCompletedRheumatoid Arthritis (RA)Taiwan
-
CHA UniversityCompleted
-
Mitsubishi Tanabe Pharma CorporationCompleted